Stella Pharma Corporation

Clinical trials sponsored by Stella Pharma Corporation, explained in plain language.

Stella Pharma Corporation 4888 TOKYO

Japanese biopharmaceutical company developing boron neutron capture therapy (BNCT) drugs.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet finished but already full! 1

New hope for tough chest tumors: targeted radiation trial launches

Disease control By invitation only

This study tests a new type of radiation therapy called BNCT for people with chest tumors that have come back and cannot be removed by surgery or treated with standard methods. About 30 participants will receive a special boron drug followed by neutron radiation to target cancer …

Phase 1/2 • Sponsor: Stella Pharma Corporation • Aim: Disease control

Last updated Jun 27, 2026 07:58 UTC

Stella Pharma Corporation

New hope for tough chest tumors: targeted radiation trial launches